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Infections with Flaviviridae viruses, such as hepatitis C virus (HCV) and dengue virus (DENV) pose global
health threats. Infected individuals are at risk of developing chronic liver failure or haemorrhagic fever re-
spectively, often with a fatal outcome if left untreated. Diseases caused by tropical parasites of the
Trypanosoma species, T. brucei and T. cruzi, constitute significant socioeconomic burden in sub-Saharan
Africa and continental Latin America, yet drug development is under-funded. Anti-HCV chemotherapy is
associated with severe side effects and high cost, while dengue has no clinically approved therapy and
antiparasitic drugs are outdated and difficult to administer. Moreover, drug resistance is an emerging con-
cern. Consequently, the need for new revolutionary chemotherapies is urgent. By utilizing a molecular
framework combination approach, we combined two distinct chemical entities with proven antiviral and
trypanocidal activity into a novel hybrid scaffold attached by an acetohydroxamic acid group (CH2-
CONHOH), aiming at derivatives with dual activity. The novel spiro-carbocyclic substituted hydantoin ana-
logues were rationally designed, synthesized and evaluated for their potency against three HCV genotypes
(1b, 3a, 4a), DENV and two Trypanosoma species (T. brucei, T. cruzi). They exhibited significant EC50 values
and remarkable selectivity indices. Several modifications were undertaken to further explore the structure
activity relationships (SARs) and confirm the pivotal role of the acetohydroxamic acid metal binding group.
Introduction
Hepatitis C virus (HCV) is a global health burden with ∼71
million people estimated to be infected.1 It is a main cause of
chronic liver disease and can lead to liver cirrhosis and hepa-
tocellular carcinoma. HCV is a member of the Flaviviridae
family and belongs to the Hepacivirus genus.2 The viral ge-
nome is a 9600 nucleotide-long single-stranded RNA of posi-
tive polarity and encodes a single polyprotein precursor,
which is processed into structural proteins (core, E1 and E2),
p7 required for assembly and release of virus particles and six
non-structural (NS) proteins (NS2, NS3, NS4A, NS4B, NS5A
and NS5B).3,4 The NS proteins form a membrane-associated
replicase complex (RC) in association with host cell factors.
HCV is classified into 8 major genotypes and at least 86 sub/
genotypes (GTs),5 with genotype 1 being the most predomi-
nant type worldwide.6
Until recently, the standard of care for HCV was ribavirin
and pegylated–interferon alpha (PEG–IFN), which had severe
side effects and low sustained virologic response (SVR)
rates.7 Since 2011, direct-acting antivirals (DAAs) targeting
the viral NS3/4A protease, the NS5B RNA-dependent RNA
polymerase (RdRp) and the NS5A phosphoprotein were intro-
duced (Fig. 1)8–11 and allowed the implementation of
interferon-free treatment schedules,12,13 which are able to at-
tain SVR in more than 90% of patients.14 DAAs efficacy dif-
fers between genotypes, with genotype 3 elimination rate be-
ing lower than the others.15,16
However, there is a risk for the development of antiviral
drug resistance, depending on the regimen and the geno-
type.17 Moreover, available DAAs are costly, limiting their
widespread clinical use, and, as a result, therapy remains low
on a global scale.18 Thus, there is still a need for novel effec-
tive drugs of lower cost.
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The mosquito-borne dengue virus (DENV) is another mem-
ber of the Flaviviridae family, belonging to the Flavivirus genus.
It causes widely distributed and endemic, visceral and central
nervous system diseases.19 Symptoms of infection range from
mild (dengue fever) to the more severe dengue hemorrhagic fe-
ver (DHF) and dengue shock syndrome (DSS).20 The recently
approved dengue vaccine has only limited overall efficacy21
and there is no approved antiviral therapy.22 DENV genome
consists of a positive single-stranded RNA of ∼11 kb in length,
encoding for the viral polyprotein, which is processed into
structural proteins (C, prM, E) and non-structural proteins
(NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5).23,24
Bivalent metal ions are important for the stability and ac-
tivity of various HCV and DENV proteins, including NS3
helicase/protease, RdRp polymerase and HCV NS5A
protein.25–30
Human African trypanosomiasis (HAT), also known as
sleeping sickness, is a vector-borne parasitic disease with 65
million people being vulnerable to infection.31 HAT occurs in
36 countries of sub-Saharan Africa and it is caused by infec-
tion with protozoan parasites belonging to the Trypanosoma
brucei sp. T. b. gambiense is the causative agent of a chronic
form of the disease (gambiense HAT, gHAT). It is prevalent in
central and western Africa, and can take years or decades to
produce a fatal outcome. T. b. rhodesiense is responsible for
an acute form disease, causing death within weeks or months
of infection. Rhodesiense HAT (rHAT) is found in eastern and
southern Africa.32,33 Clinical progression of both forms of
HAT is divided in two stages. The early hemolymphatic stage
and the late meningoencephalitic stage when the parasites
enter the central nervous system causing neurological dam-
age and sleep disturbances.34
Treatment approaches of HAT consist of five drugs: penta-
midine, suramin, melarsoprol, eflornithine, and nifurtimox–
eflornithine combination therapy (NECT) (Fig. 2). Neverthe-
less, their increasing levels of resistance, their limited effi-
cacy, toxicity and adverse side effects, make HAT treatment a
daunting challenge.35 Fexinidazole and acoziborole (Fig. 2)
are two potential drug candidates, currently being in ad-
vanced clinical trials.36,37
American trypanosomiasis, or Chagas disease, is a poten-
tially life-threatening infection caused by the protozoan para-
site Trypanosoma cruzi. It is endemic in continental Latin
America, with a devastating effect upon 6–7 million people,38
and it is characterized by two distinct clinical phases: an
acute mostly asymptomatic phase, and a chronic phase char-
acterized mainly by cardiac disorders.39 The two drugs avail-
able, nifurtimox and benznidazole (Fig. 2), are only partially
effective and toxic side effects limit their use.40
Unfortunately, there is no efficient disease management
for both parasitic infections and the World Health Organiza-
tion has listed them among the neglected tropical diseases
(NTDs). Therefore, in absence of vaccines, development of
novel effective therapeutics is an imperative for their treat-
ment and control.33
Several groups of trypanosomatid metalloenzymes have
been identified as playing an important role in the metabo-
lism and viability of parasites. Amongst the most widely ex-
plored are histone deacetylases (HDACs), trypanosome alter-
native oxidase (TAO) and carbonic anhydrase (CA).41–48
Metalloenzymes' inhibition appears attractive as a chemo-
therapeutic approach against viruses and parasites.47–53 It
has been proved that the vast majority of metalloenzyme in-
hibitors are chelating agents employing metal binding groups
to coordinate the active site metal ion.54,55 As a continuation
of our research on metal chelating agents,56,57 we were inter-
ested in developing novel combined scaffolds demonstrating
both antiviral and antiparasitic properties.
Fig. 2 Currently available marketed drugs for treatment of HAT and
Chagas disease. Highlighted regions are reported to play a major role
in the mechanism of action. Chemical structures of potential drug
candidates fexinidazole and acoziborole.
Fig. 1 Representative chemical structures of clinically approved DAAs
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In this study, we report the rational design and synthesis
of novel spiro-hydantoin analogues, attached by the aceto-
hydroxamic acid moiety (CH2CONHOH) as the potential
metal binding functional group (Fig. 3). Several bicyclic fused
rings were used as spiro-substituents on the basic 2,4-
diketoimidazolidine scaffold, while methyl- and benzyl-
groups were incorporated at the amide nitrogen atom of
hydantoin, to enhance binding affinity and improve drug-
likeness of the compounds. The novel analogues were
assessed as antiviral and trypanocidal agents and exhibited
remarkable inhibitory activity with respect to their parent
compounds I and II. More specifically, they were evaluated
for their effect on RNA replication and cell viability on differ-
ent HCV genotypes (1b, 3a, 4a) and DENV. Their antiparasitic
activity was assessed based on their ability to inhibit prolifer-
ation of cultured bloodstream form T. brucei and T. cruzi epi-
mastigotes in vitro.
Results and discussion
Rational design – theoretical calculations
Previous studies by our group have resulted in compounds
carrying metal chelating moieties that demonstrated a highly
promising inhibition capacity against either pathogenic vi-
ruses, including influenza and HCV,56 or parasites of the
Trypanosoma genus.57,58 The two above-mentioned series of
analogues, although structurally diverse, were based on ratio-
nal incorporation of metal chelating moieties on scaffolds
with pronounced drug-likeness, such as the combination of
flutimide with the indole system (I) or incorporation of the
acetohydroxamic acid moiety on a 2,6-diketopiperazine (2,6-
DKP) scaffold (II) (Fig. 3). In the present study, a conceptual
approach to further exploit the bioactivity of molecules with
potential metal chelating efficacy toward designing effectors
with inhibitory activity against both disease-related viruses
and Trypanosoma parasites is reported. The design was based
on combination of the exocyclic acetohydroxamic acid
pharmacophore, bearing well proven trypanocidal activity,
with a lipophilic tail based on a bicyclic system-substituted
hydantoin that could effectively mimic the antiviral flutimide
scaffold yet with increased steric bulk, thus affording a novel
synthetically tractable heterocyclic scaffold as presented in
detail in Fig. 3.
To counterbalance possible issues of water solubility aris-
ing from the tricyclic system of the antiviral lead I, we se-
lected to enhance the sp3 character of the novel scaffold by
introducing a spiro connection between the acetohydroxamic
group-carrying hydantoin and the indane system. In this
case, resembling the spiro trypanocidal lead II would contrib-
ute toward avoiding possible Lipinski's rule-of-five violations.
Hence, the indole nitrogen atom was converted to a carbon,
giving rise to a hydrophobic indane (compound 16). More-
over, with the aim of evaluating the contribution of the criti-
cal parameter of lipophilicity on biological activity, exten-
sions of the indane system to tetralin or benzocycloheptane
were considered (compounds 17 and 18), while the addition
of alkyl substituents such as methyl- or benzyl-groups on N3
of hydantoin was also explored (compounds 16a, 17a, 18a
and 16b, 17b, 18b respectively). To confirm the importance
of the exocyclic acetohydroxamic acid moiety on antiviral and
trypanocidal activity, the derivative 4, lacking metal chelating
ability, was evaluated as a negative control (Tables 1 and 2).
The derivative 16 carrying the smallest steric bulk, i.e. an
indane system with no substitution on N3, was selected for
probing the validity of our approach.
Compound 16 was synthesized and subsequently tested
against HCV (replicon 1b) and bloodstream form T. brucei
in vitro, exhibiting significant inhibitory activity against both
targets. More specifically, the EC50 value for HCV was in the
low micromolar range (EC50 16 = 2.92 μM, Table 1) and for T.
brucei was in the nanomolar range (EC50 16 = 0.44 μM,
Table 2), identifying this particular acetohydroxamic acid de-
rivative as a promising and original lead compound. All the
aforementioned designed analogues were also synthesized
and tested against two different genotypes of HCV (1b and
4a) and against two Trypanosoma species. Analogues 16, 17
and 18 were also tested against HCV genotype 3a and DENV.
The resulting EC50 and cytotoxicity values are presented in
Tables 1 and 2.
Chemistry
As depicted in Scheme 1, the commercially available ke-
tones 1–3 (Scheme 1A) were subjected to Bucherer–Bergs re-
action with ammonium carbonate and potassium/sodium
cyanide in EtOH/H2O. Treatment of the resulting
hydantoins 4–6 with potassium bisĲtrimethylsilyl)amide in
dry THF afforded the corresponding potassium imidate
salts. The latter intermediates were converted to the respec-
tive benzyl esters 7–9 upon SN2 reaction with benzyl
Fig. 3 Indole–flutimide analogue (I) with antiviral activity,
cycloheptane spiro-substituted 2,6-DKP analogue (II) with trypanocidal
activity and novel synthesized analogues reported in this study. Metal
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bromoacetate in dry DMF, as described in our previously
published protocols.59,60 Catalytic hydrogenolysis (Pd/C
10%) of the aforementioned benzyl esters led to the carbox-
ylic acids 10–12, which were further converted to the corre-
sponding O-benzyl hydroxamates 13–15 upon coupling with
O-benzylhydroxylamine·HCl in the presence of CDI or
EDCI·HCl, HOBt. Finally, removal of the protective group
was accomplished with hydrogenolysis, yielding almost
quantitatively the target acetohydroxamic acids 16–18.
For the synthesis of the N-alkylated analogues, the precur-
sors benzyl esters 7–9 were reacted with NaH and the corre-
sponding alkyl halide in dry DMF. Surprisingly, in the case of
N-methylation procedure, transesterification products (methyl
esters) were also isolated (Scheme 1C), along with the
expected N-methylated benzyl esters.59 Employment of the
previously described methodology, catalytic hydrogenolysis of
the benzyl esters 7a–9a and 7b–9b, followed by amidation
and deprotection of the amides 13a–15a and 13b–15b,




Screening of compounds using an HCV genotype 1b replicon
system. The effects of analogues 16–18, 16a–18a, 16b–18b and
4 on HCV RNA replication and cell viability were determined
in the stable cell line Huh5-2 containing an HCV genotype 1b
(strain Con1) replicon encoding the firefly luciferase gene.61
In this cell system, the level of expressed luciferase directly
correlates with the level of HCV RNA replication. Using serial
dilutions of the compounds, the half maximal effective con-
centration (EC50) and the median cytotoxic concentration
(CC50) were obtained, by measuring HCV replication-driven
luciferase activity and intracellular ATP levels, respectively
(Table 1, Fig. 4A). Dose–response curve analysis is presented
for the most potent analogue 18 (Fig. 4B). Selectivity indices
(SI) = CC50/EC50 were calculated for all analogues
synthesized.
As shown in Table 1, acetohydroxamic acid analogues
were potent against HCV-1b replication, with EC50 values
ranging from 0.22 to 2.92 μM. Compounds 16b, 17b and 18
exhibited the highest inhibitory activity, with EC50s in the
submicromolar range (0.22 μM, 0.32 μM and 0.25 μM, respec-
tively). We observed that the replacement of indane ring of
16 with the bulkier tetralin (17) and benzocycloheptane (18)
rings progressively increased the activity of the compounds.
It is noteworthy that the activity of 18 (EC50 = 0.25 μM) was
12-fold better than lead compound 16 (EC50 = 2.92 μM). A
marked improvement was also observed on the EC50 value of
16 (43-fold lower), compared to the structurally related fused
indole–flutimide analogue I (EC50 = 126.3 μM),
56 validating
the idea of incorporating a spiro connection between
hydantoin and the indane ring. Introduction of a methyl
Table 1 In vitro inhibitory activity of compounds 16–18, 16a–18a, 16b–18b and hydantoin analogue 4 tested against HCV (genotypes 1b, 3a, 4a) and
DENV (serotype 2). Cytotoxicity against Huh5-2, HCV replicon cells and selectivity indices
Structure Cmpd R
HCV-1b HCV-3a HCV-4a DENV-2
CC50
c (μM)EC50
a (μM) SIb EC50
a (μM) SIb EC50
a (μM) SIb EC50
a (μM) SIb
16 H 2.92 ± 0.01 >68 2.97 ± 0.21 >67 0.58 ± 0.04 >345 96.34 ± 1.00 >2 >200
16a CH3 1.41 ± 0.01 19 — — 0.21 ± 0.02 128 — — 26.91 ± 0.67
16b CH2Ph 0.22 ± 0.01 34 — — 0.14 ± 0.01 54 — — 7.53 ± 1.29
17 H 1.41 ± 0.35 >142 2.37 ± 0.17 >84 0.38 ± 0.04 >526 61.49 ± 3.86 >3 >200
17a CH3 1.45 ± 0.07 99 — — 0.21 ± 0.01 682 — — 143.2 ± 0.37
17b CH2Ph 0.32 ± 0.01 28 — — 0.07 ± 0.02 127 — — 8.90 ± 0.77
18 H 0.25 ± 0.02 794 0.08 ± 0.01 2480 0.10 ± 0.00 1984 16.29 ± 2.17 12 198.4 ± 2.24
18a CH3 1.18 ± 0.07 95 — — 0.11 ± 0.01 1015 — — 111.6 ± 12.43
18b CH2Ph 1.00 ± 0.05 5 — — 0.12 ± 0.01 45 — — 5.45 ± 0.27
4 H >10 — — — — — — — >10
I — 126.30 ± 14.20 >1.6 — — — — — — >200
a EC50 (median effective concentration) values represent the mean ± SD of three independent experiments, each carried out in triplicate.
Calculated against HCV genotype 1b (Huh5-2, HCV 1b replicon cells), genotype 3a (Huh7.5-3a, HCV 3a replicon cells), genotype 4a (Huh7.5-4a,
HCV 4a replicon cells). b Selectivity index: CC50/EC50.
c CC50 (median cytotoxic concentration against Huh5-2, HCV replicon cells) values
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substituent on the amide nitrogen atom of the 2,4-
diketoimidazolidine scaffold of 16 led to a 2-fold increase in
the activity (EC50 16a = 1.41 μM). However, this methylation
had almost no effect in the potency of 17 (EC50 17 = 1.41 μM;
EC50 17a = 1.45 μM) and resulted in lower inhibitory potency
for the N-methylated analogue 18a (EC50 18a = 1.18 μM). The
addition of the bulky lipophilic benzyl substituent to the
same nitrogen atom of the hydantoin scaffold led to lower
EC50 values for the resulting analogues 16b (EC50 = 0.22 μM)
and 17b (EC50 = 0.32 μM), as compared to the addition of the
methyl substituent. On the other hand, the benzyl group de-
creased the activity of compound 18b 4-fold with respect to
the corresponding NH-analogue 18. In the case of the
hydantoin 4, the lack of activity underlines the importance of
the acetohydroxamic acid metal binding group for the anti-
viral potency of the compounds.
Concerning the cytotoxicity evaluation (Table 1), all the
non-substituted analogues 16, 17 and 18 exhibited high CC50
values (≥200 μM), which resulted in remarkable selectivity in-
dices. The most promising analogue appears to be compound
18, with SI value of 794. It is of great interest that the incor-
poration of an alkyl substituent onto the amide nitrogen
atom progressively increased the cytotoxicity of the com-
pounds, in agreement with the higher lipophilicity deter-
mined by calculated logD values (Table 2); the bulkier the li-
pophilic substituent, the lower the CC50 value.
Activity of the compounds against other HCV genotypes. As
the compounds exhibited significant potency against HCV
genotype 1b, they were selected for further testing against
other HCV genotypes. Specifically, we determined viral
replication-derived luciferase activity in Huh7.5-3a stable cell
line for compounds 16, 17 and 18 and in Huh7.5-4a stable
cell line for compounds 16–18, 16a–18a and 16b–18b,
containing subgenomic replicons of HCV genotype 3a (isolate
S52) and 4a (isolate ED43), respectively.
Similar to genotype 1b, the activity of 16, 17 and 18
against HCV genotype 3a ranged from low micromolar to
nanomolar, and the increase in ring size conferred higher po-
tency. Specifically, EC50 values were below 2.97 μM, with the
most promising analogue being compound 18 (EC50 18 =
0.08 μM; SI 18 = 2480), whose activity was 3-fold higher com-
pared to the one exhibited in HCV-1b.
Biological evaluation of the hydroxamic acid derivatives
on HCV-4a indicated enhanced activity as compared to geno-
types 1b and 3a. All the novel synthesized analogues
inhibited HCV-4a replication at submicromolar concentra-
tions, ranging from 0.07 μM for 17b to 0.58 μM for the
indane substituted analogue 16. Tetralin substitution
Table 2 Activity of acetohydroxamic acid analogues 16–18, 16a–18a, 16b–18b and hydantoin analogue 4 tested against cultured bloodstream form T.
brucei (pH 7.4) and T. cruzi epimastigotes. Cytotoxicity against cultured rat skeletal myoblast L6 cells, selectivity indices, logD and pKa values
Structure Cmpd R











a (μM) SIb EC50
a (μM) EC90
a (μM) SIb
16 H 0.44 ± 0.08 0.80 ± 0.02 609 >30 >30 — 268 ± 9 −0.24 9.1
16a CH3 1.22 ± 0.39 1.93 ± 0.45 451 >30 — — 550 ± 24 −0.01 9.0
16b CH2Ph 0.101 ± 0.003 0.192 ± 0.003 62 1.70 ± 0.06 3.01 ± 0.36 4 6.27 ± 0.60 1.71 9.5
17 H 0.71 ± 0.12 1.27 ± 0.02 590 >30 >30 — 419 ± 55 0.21 9.3
17a CH3 1.91 ± 0.23 4.69 ± 0.10 15 27.6 ± 5.3 42.1 ± 2.4 1 28.2 ± 1.0 0.43 9.0
17b CH2Ph 0.050 ± 0.003 0.077 ± 0.021 63 0.96 ± 0.03 1.71 ± 0.07 3 3.17 ± 0.48 2.16 9.2
18 H 0.40 ± 0.04 0.52 ± 0.05 313 >30 — — 125 ± 12 0.65 9.3
18a CH3 0.23 ± 0.01 0.30 ± 0.01 71 10.6 ± 0.6 15.3 ± 0.2 2 16.4 ± 1.1 0.88 9.2
18b CH2Ph 0.013 ± 0.002 0.018 ± 0.001 604 0.495 ± 0.058 0.94 ± 0.033 16 7.85 ± 0.33 2.60 9.4
4 H >50 — — >500 — — >500 0.89 n.a.
II — 1.87 ± 0.08 2.53 ± 0.29 — — — — — — —
a Concentrations required to inhibit growth of T. brucei and T. cruzi by 50% and 90%, respectively. EC50 and EC90 data are the mean of
triplicate experiments ± SEM. b Selectivity indices were calculated as the ratio of the CC50 for L6 cells to EC50 for T. brucei or T. cruzi
respectively. c Cytotoxicity was determined by establishing the concentration required to inhibit growth of cultured L6 cells by 50% (CC50).
Data are the mean of triplicate experiments ± SEM. d logD at pH 7.4 determined using Marvin.62 e pKa values for the oxime proton determined
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increased the activity by 1.5 times (EC50 17 = 0.38 μM) and
benzocycloheptane by 6 times (EC50 18 = 0.10 μM).
Moreover, N-methyl substitution on the hydantoin ring
had a favorable effect on the antiviral activity, but only in
the context of the indane- and tetralin-substituted analogues
(EC50 16a = 0.21 μM; EC50 17a = 0.21 μM). The
N-methylated analogue 18a exhibited potency similar (in the
order of 0.1 μM) to the parent compound 18. The same
trend was observed for the N-benzyl counterparts 16b and
17b, which were found to be 4 and 5.5 times more potent
than their parent compounds 16 and 17, respectively,
whereas compound 18b was equipotent (EC50 18b = 0.12
μM) to the NH and N-methyl congeners (EC50 18 = 0.10 μM
and EC50 18a = 0.11 μM, respectively). The increased activity
of the compounds in HCV genotype 4a, as compared to the
other genotypes, resulted in higher SI values, which ranged
from >345 to 1984 for the NH analogues 16, 17 and 18. As
for the N-methylated analogues, the most selective were 17a
(SI 682) and 18a (SI 1015). Finally, out of all compounds,
the most promising appeared to be 18, whose SI values
were significantly high: 794, 2480 and 1984 for genotypes
1b, 3a and 4a, respectively.
Validation of compounds 17a and 18 activity with additional
assays. The inhibition profile of the most potent and safe
compounds from the tetralin and benzocycloheptane groups,
as measured by luciferase assay, was confirmed by
determining viral RNA and NS5A protein levels. As the
compounds showed higher activity against HCV genotype 4,
Huh7.5-4a replicon cells were used for validating activity.
Specifically, cells were treated with serial dilutions of
compounds 17a or 18, or the solvent DMSO (control) and
viral RNA was quantified by reverse transcription-quantitative
polymerase chain reaction (RT-qPCR) whereas NS5A was eval-
uated by indirect immunofluorescence. We observed that
Scheme 1 A) Starting ketones B) synthesis of the target acetohydroxamic acid analogues 16–18, 16a–18a and 16b–18b. Reagents and conditions:
(a) method A: NaCN (2.27 eq.), (NH4)2CO3 (6 eq.), EtOH/H2O (1.1 : 1), reflux, 8 h–11 days; | method B: KCN (1.3 eq.), (NH4)2CO3 (5 eq.), EtOH/H2O
(1 : 3), MW (100 W), 120 °C, 25 min–1 h; (b) (i) [(CH3)3Si]2NK (1.02 eq.), dry THF (0–5 °C) and then r.t., 20 min–1 h, argon; (ii) BrCH2COOCH2Ph (1.05
eq.), dry DMF, 35–38 °C, 48 h, argon; (c) (i) NaH (1.2 eq.), dry DMF, (0–5 °C) and then r.t., 15 min, argon; (ii) PhCH2Br (1.2 eq.), 60 °C, 7 days, argon;
(d) H2, Pd/C 10%, EtOH/AcOEt 3 : 1, 50–55 psi, 40–45 °C, 3 h; (e) method A: EDCI·HCl (1.2 eq.), HOBt (1.2 eq.), PhCH2ONH2·HCl (1.2 eq.), TEA (5.8
eq.), dry CH2Cl2/dry DMF, 30–35 °C, 40 h, argon; | method B: (i) CDI (1.2 eq.), dry THF, 28–30 °C, 1 h, argon; (ii) PhCH2ONH2·HCl (1.2 eq.), TEA
(1.82 eq.), 28–30 °C, 24 h, argon; (f) H2, Pd/C 10%, EtOH/AcOEt 3 : 1, 50–55 psi, 40–45 °C, 3 h. C) Methyl esters obtained because of unexpected
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compounds 17a and 18 caused a reduction in HCV RNA repli-
cation (Fig. 5A), with EC50s similar to those calculated on the
basis of virus-derived luciferase activity (Table 1). Consistent
results were obtained by indirect immunofluorescence analy-
sis of HCV NS5A in Huh7.5-4a replicon cells treated with
compound 18, which were best visible at high compound
concentration (Fig. 5B). Nuclei were stained with propidium
iodide (PI) as a cell viability control.
Activity of the compounds against DENV. Taking into
account the broad activity of the compounds against
different HCV genotypes, they were also tested against the
closely related DENV. Both HCV and DENV belong to the
same family (Flaviviridae) and express metalloenzymes,
which are potential targets of our compounds. To examine
the anti-DENV activity of the non-substituted analogues (16,
17 and 18), we determined viral replication-derived luciferase
activity in Huh7-D2 stable cell line containing the
subgenomic replicon of DENV serotype 2 (strain 16681).
Interestingly, the order of activity obtained with 16, 17 and
18 was the same when they were tested against DENV. Com-
pound 16 exhibited the lowest inhibitory activity (EC50 =
96.34 μM), which was progressively increased along with the
bulkiness of the spiro-substituent, resulting in an EC50 value
of 16.29 μM for analogue 18.
Trypanocidal assays
Activity of the compounds against T. brucei. Acetohydroxamic
acid derivatives exhibited considerable trypanocidal activity
against T. brucei, with EC50s ranging from 0.013 to 1.91 μM.
Compounds 18b and 17b were the most potent against African
trypanosomes with low nanomolar EC50 values (13 nM and 50
nM respectively, Table 2), while hydroxamates 16b, 17b and
18b were also significantly active against T. cruzi epimastigotes,
with EC50 values in the low micromolar range.
Changing the indane ring in structure 16 with the tetralin
ring decreased the activity, with the EC50 value of 17 being
1.5-fold higher (EC50 = 0.71 μM). Somewhat surprisingly, the
replacement of indane by benzocycloheptane led to com-
pound 18, which was almost equipotent to lead compound
16 (EC50 16 = 0.44 μM; EC50 18 = 0.40 μM). These molecules
appeared to confer a beneficial effect on the trypanocidal po-
tency, with respect to the structurally related cycloheptane
spiro-substituted 2,6-DKP analogue II (EC50 = 1.87 μM),
57 in-
dicating that the fused bicyclic systems that were used as
substituents at position 4 of the hydantoin core were a favor-
able structural modification.
Methyl substitution on the amide nitrogen atom of the
respective 2,4-diketoimidazolidine residue of the parent com-
pound 18 led to a 2-fold increase in potency for the benzo-
cycloheptane substituted analogue 18a. On the other hand,
incorporation of a methyl substituent in 16 and 17, lowered
the activity observed in the N-methylated analogues 16a and
17a, with EC50 values 1.22 μM and 1.91 μM respectively. They
were almost 3 times less potent than the corresponding NH-
analogues (Table 2).
Addition of the bulky hydrophobic benzyl substituent to
the same nitrogen atom of the hydantoin scaffold yielded an-
alogues that were extremely potent against T. brucei, as exem-
plified by compounds 16b, 17b and 18b (Table 2). Their activ-
ities were respectively 4.5, 14 and 31 times higher than the
parent compounds 16, 17 and 18. All the N-benzylated ana-
logues retained high potency, with EC50 values ranging be-
tween 13 and 101 nM (Table 2). It is noteworthy that the in-
corporation of a benzyl group in the corresponding non-
substituted precursors 16, 17 and 18 progressively increased
activity against T. brucei in vitro. This enhanced potency of
analogues 16b, 17b and 18b reflects the strongly favorable
stereoelectronic and hydrophobic effects exerted by the ben-
zyl substituent in the binding site.
The cytotoxicity of all target compounds against mamma-
lian cells was determined using the rat skeletal myoblast L6
Fig. 4 A) Screening of compounds against HCV genotype 1b replication. Huh5-2 cells, harboring HCV genotype 1b (Con1) subgenomic replicon,
were seeded at 30% confluency and treated for 72 h with the compounds at 3 μM. B) Activity of compound 18, against HCV genotype 1b, 3a and
4a RNA replication, using dose–response curve analysis. Huh5-2, Huh7.5-3a and Huh7.5-4a cells, harboring subgenomic replicons of HCV geno-
type 1b (Con1), 3a (S52) or 4a (ED43), respectively, were seeded at 30% confluency and treated for 72 h with serial dilutions of 18. In both A and B,
as a marker of viral RNA replication, firefly luciferase activity was determined and calculated as relative light units (RLU) per μg of total protein.
Values obtained with compound-treated cells were expressed as percentage of those obtained with cells treated with the solvent DMSO (control).
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cell line. Notably, the non-substituted analogues 16, 17 and
18 displayed very low cytotoxicity against mammalian cells,
having CC50s in the 125–419 μM range, thus resulting in re-
markable selectivity indices, which varied from 313 (18) to
609 (16). In general, as in the case of HCV, it was observed
that the incorporation of an alkyl substituent onto the amide
nitrogen atom progressively increased the cytotoxicity of the
compounds, with the exception of compound 16a (CC50 = 550
μM, SI 451). Finally, the acetohydroxamic acid derivative 18b,
which had the highest activity against T. brucei (EC50 = 0.013
μM) displayed a very good selectivity (SI 604), despite the
benzyl substitution.
Activity of the compounds against T. cruzi. Compounds
were also tested against cultured T. cruzi epimastigotes, with
EC50 values at submicromolar to micromolar levels (0.49–27.6
μM) (Table 2). Acetohydroxamic acid derivatives with a
substituent on the amide nitrogen atom were able to inhibit
parasite growth, an effect that was not observed with the
non-substituted derivatives. More specifically, compounds 16,
17 and 18 exhibited no activity at the highest concentration
tested (30 μM), whereas the N-methylated analogues showed
medium inhibitory activity (EC50 17a = 27.6 μM; EC50 18a =
10.6 μM), with the only exception being analogue 16a. It is of
great importance that the incorporation of a benzyl group
resulted in unexpectedly potent analogues. The EC50s
obtained ranged from 0.49 μM for the bulkier analogue 18b
to 1.70 μM for the indane analogue 16b, indicating the posi-
tive effect of increasing the bulkiness and lipophilicity of the
compounds, a pattern also observed in T. brucei sp. Interest-
ingly, activity of the N-benzylated analogue 18b was 21.5-fold
higher than the N-methylated counterpart 18a. For the respec-
tive tetralin analogue 17b, this increase in potency was 29
times higher. Finally, the absence of the acetohydroxamic
acid moiety was detrimental for the activity against blood-
stream form T. brucei and T. cruzi epimastigotes (Table 2),
suggesting that the hydroxamic acid unit is essential also for
the trypanocidal activity.
Concerning the physicochemical parameters of the pre-
pared analogues, enhanced lipophilicity quantified by calcu-
lated logD values seems to be important to their bioactivity,
and in most cases beneficial in terms of their capacity as
drug leads. Conversely, pKa values of the various analogues
do not demonstrate significant difference and thus they do
not appear to contribute to the observed structure–activity
relationships.
Biological evaluation indicates that metalloproteins may
constitute the targets of the acetohydroxamic acid-based ana-
logues described herein. However, binding and pulldown as-
says will be helpful to fully rationalize the observed bioactiv-
ity and determine the exact molecular targets of the novel
analogues, thus facilitating structure-based design of meta-
lloenzyme inhibitors.
Conclusions
In summary, despite the small overlapping degree between
the starting frameworks I and II, we have successfully
designed and synthesized compounds with dual activity, by
merging two distinct scaffolds into a single chemical entity.
The framework combination strategy involved the integration
of structural elements from indole–flutimide analogues,
exhibiting antiviral potency, with spiro carbocyclic 2,6-DKP
acetohydroxamic acid-based trypanocidal agents, in order to
achieve both activities into a single lead molecule. The novel
bicyclic substituted hydantoin analogues not only exhibited
individually improved antiviral and antiparasitic activity com-
pared to analogues I and II, but also demonstrated excep-
tional inhibitory activity against different HCV genotypes (1b,
3a, 4a) and DENV, as well the two Trypanosoma species (T.
brucei, T. cruzi). Structure–activity relationships deduced from
the biological results suggest that the increased size of the
spiro-substituent generally favors inhibitory activity towards
the targets of interest. Moreover, activity is enhanced upon
Fig. 5 Inhibitory effect of compounds on HCV RNA levels and protein
expression in a subgenomic HCV Con1 replicon assay. A)
Quantification of (+) strand HCV RNA by RT-qPCR in Huh7.5-4a repli-
con cells treated with serial dilutions of compounds 17a, 18 or the sol-
vent DMSO. Values from compound-treated cells are expressed as
percentage of those obtained with cells that received the solvent (con-
trol). mRNA levels of the housekeeping gene YWHAZ were used for
normalization. B) Indirect immunofluorescence for NS5A (left panels)
in Huh7.5-4a replicon cells, treated with serial dilutions of compound
18 or the solvent DMSO. Nuclei were stained with propidium iodide
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increasing the lipophilicity of the compounds, particularly
via introduction of a methyl- or benzyl-substituent at the am-
ide nitrogen atom of the hydantoin ring. In fact, the results
suggest that increasing the bulkiness of the substituent im-
proves rather than retards activity. Along with the lipophilic-
ity, the acetohydroxamic acid moiety, capable of chelating ac-
tive site metal ion(s), is an indispensable component of this
class of inhibitors, since removal of this functional group
from the imidic nitrogen atom caused a dramatic loss of ac-
tivity. Finally, the remarkable selectivity indices observed for
most of the tested analogues indicate that the novel scaffold
of an appropriately substituted hydantoin ring and a metal
binding moiety may be the key to unlock multiple pathogen




Experimental methods. During the conduct of the experi-
mental part of the present study were used the following ma-
terials, apparatuses and techniques. Melting points were de-
termined using a Büchi capillary apparatus and are
uncorrected. NMR experiments were performed to elucidate
the structure and determine the purity of the newly synthe-
sized compounds. 1H NMR and 2D NMR spectra (COSY,
HSQC, HSQC-DEPT and HMBC) were recorded on a Bruker
DRX400 spectrometer (400.13 MHz, 1H NMR) and a Bruker
Ultrashield™ Plus Avance III 600 spectrometer (600.11 MHz,
1H NMR). 13C NMR and DEPT NMR spectra were recorded on
a Bruker Avance 200 spectrometer (50.32 MHz, 13C NMR) and
a Bruker Ultrashield™ Plus Avance III 600 spectrometer
(150.9 MHz, 13C NMR). Chemical shifts δ (delta) are reported
in parts per million (ppm) downfield from the NMR solvent,
with the tetramethylsilane or solvent (DMSO-d6) as internal
standard. Data processing including Fourier transformation,
baseline correction, phasing, peak peaking and integrations
were performed using MestReNova software v.12.0.0. Splitting
patterns are designated as follows: s, singlet; br s, broad sin-
glet; d, doublet; br d, broad doublet; t, triplet; q, quartet; dd,
doublet of doublets; ddd, doublet of doublets of doublets;
dddd, doublet of doublets of doublets of doublets; ddddd,
doublet of doublets of doublets of doublets of doublets; dt,
doublet of triplets; dq, doublet of quartets; ddt, doublet of
doublets of triplets; ddq, doublet of doublets of quartets; dtt,
doublet of triplets of triplets; dqt, doublet of quartets of trip-
lets; ddtd, doublet of doublets of triplets of doublets; td, trip-
let of doublets; tdd, triplet of doublets of doublets; qt, quartet
of triplets; m, multiplet; complex m, complex multiplet. Cou-
pling constants (J) are expressed in units of Hertz (Hz). The
spectra were recorded at 293 K (20 °C) unless otherwise speci-
fied. The solvents used to obtain the spectra were: deuterated
chloroform, CDCl3 (s, 7.26 ppm,
1H NMR; t, 77.16 ppm, 13C
NMR), deuterated dimethyl sulfoxide, DMSO-d6 (quin, 2.50
ppm, 1H NMR; septet, 39.52 ppm, 13C NMR) and deuterated
methanol, MeOD-d4 (quin, 3.31 ppm,
1H NMR; septet, 49.00
ppm, 13C NMR). Analytical thin-layer chromatography (TLC)
was used to monitor the progress of the reactions, as well as
to authenticate the compounds. TLCs were conducted on,
precoated with normal-phase silica gel, aluminium sheets
(Silica gel 60 F254, Merck) (layer thickness 0.2 mm). Devel-
oped plates were examined under a UV light source, at wave-
lengths of 254 nm and 365 nm, or after being stained by io-
dine vapors. The Retention factor (Rf) of the newly
synthesized compounds, that equals to the distance migrated
over the total distance covered by the solvent, was also mea-
sured on the chromatoplates. Column chromatography tech-
nique was used to isolate the desired compounds from by-
products of reactions, and it was carried out using elution
solvents of increasing polarity in a stationary phase of SiO2
(Silica gel 60, 40–63 μm, 230–400 mesh ASTM, Silica flash).
Column packing was done using the slurry method, while the
mixtures to be analyzed were loaded using either the tech-
nique of dry deposition, or as a solution in the first eluent
where this was possible. Elemental analyses (C, H, N) were
performed by the Service Central de Microanalyse at CNRS
(France), and were within ±0.4% of the theoretical values. Ele-
mental analysis results for the tested compounds correspond
to >95% purity. The commercial reagents were purchased
from Alfa Aesar, Sigma-Aldrich, and Merck, and were used
without further purification, except for the benzyl bromo-
acetate. This reagent was purified by fractional distillation in
vacuo prior to use. Organic solvents used were in the highest
purity, and when necessary, were dried by the standard
methods. Solvent and reagent abbreviations: THF, tetrahydro-
furan; DMF, N,N-dimethylformamide; Et2O, diethyl ether;
AcOEt, ethyl acetate; EtOH, ethanol; MeOH, methanol;
EDCI·HCl, N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide
hydrochloride; HOBt, 1-hydroxybenzotriazole hydrate; CDI,
1,1′-carbonyldiimidazole; TEA, triethylamine.
General experimental procedures
General experimental procedure for the preparation of car-
boxylic acids 10–12, 10a–12a and 10b–12b. A solution of the
appropriate benzyl ester 7–9, 7a–9a and 7b–9b (2.0 mmol) in
a mixture of EtOH/AcOEt 3 : 1 (40 mL) was hydrogenated for 3
h at 40–45 °C and 50–55 psi pressure, in the presence of Pd/
C (10 wt%) as a catalyst. The catalyst was filtered off, washed
with portions of hot MeOH (3 × 15 mL) and the combined fil-
trates were evaporated under reduced pressure to yield the
corresponding carboxylic acids 10–12, 10a–12a and 10b–12b.
General experimental procedure for the preparation of
N-(phenylmethoxy)acetamides 13–15, 13a–15a and 13b–15b
Method A. To a solution of the appropriate carboxylic acid
(10, 12, 12b) (2.0 mmol, 1.0 eq.) in 20 mL dry CH2Cl2/dry
DMF (4 : 1), EDCI·HCl (2.4 mmol, 1.2 eq.), HOBt (2.4 mmol,
1.2 eq., 80% monohydrate), O-benzylhydroxylamine
hydrochloride (2.4 mmol, 1.2 eq.) and TEA (11.6 mmol, 5.8
eq.) were added sequentially. The reaction mixture was
stirred for 40 h, at 30–35 °C under argon. After removal of
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and the mixture was extracted with AcOEt (4 × 40 mL). The
combined organic layers were washed with H2O (3 × 70 mL)
and brine (2 × 70 mL), dried over anh. Na2SO4 and evapo-
rated in vacuo. The crude residue was purified by column
chromatography on silica gel using a mixture of CH2Cl2/
AcOEt and AcOEt as eluents to afford the desired amides (13,
15, 15b respectively).
Method B. The appropriate carboxylic acid (11, 10a–12a,
10b, 11b) (2.0 mmol, 1.0 eq.) was treated with CDI (2.4
mmol, 1.2 eq.) in dry THF (26 mL) and the mixture was
stirred for 1 h, at 28–30 °C under argon. Then,
O-benzylhydroxylamine hydrochloride (2.4 mmol, 1.2 eq.) and
TEA (3.64 mmol, 1.82 eq.) were added successively, and the
stirring was continued for 24 h, at 28–30 °C under Ar. After
removal of the solvent in vacuo, the reaction mixture was
quenched with ice-water (40 mL) and extracted with AcOEt (4
× 40 mL). The combined organic phases were washed with
H2O (3 × 70 mL) and brine (2 × 70 mL), dried with anh.
Na2SO4 and evaporated under reduced pressure. The crude
residue was purified by column chromatography on silica gel
using a mixture of CH2Cl2/AcOEt and AcOEt as eluents to af-
ford the desired amides (14, 13a–15a, 13b, 14b respectively).
General experimental procedure for the preparation of the
hydroxamic acids 16–18, 16a–18a and 16b–18b. 10 wt% Pd
on charcoal was added to a solution of the appropriate
O-benzyl hydroxamate (13–15, 13a–15a, 13b–15b) (1.0 mmol)
in a mixture of EtOH/AcOEt 3 : 1 (40 mL). After 3 h of shaking
under an atmosphere of 50–55 psi hydrogen, at 40–45 °C, the
catalyst was removed by filtration and washed with hot
MeOH (3 × 15 mL). The combined filtrates were concentrated
to dryness under reduced pressure to afford the title aceto-
hydroxamic acid analogues (16–18, 16a–18a and 16b–18b
respectively).
General N-benzylation procedure for the preparation of
analogues 7b–9b. The appropriate benzyl ester (7–9) (2.6
mmol, 1.0 eq.) was dissolved in 12 mL dry DMF and was
treated with small portions of NaH (3.12 mmol, 1.2 eq., 60%
dispersion in mineral oil) under ice-cooling. After 15 min of
stirring at r.t. under argon, benzyl bromide was added
dropwise (3.12 mmol, 1.2 eq.). After 7 days of stirring at 60
°C, under argon, the mixture was poured into 120 mL ice-
water and extracted with AcOEt (3 × 90 mL). The combined
organic layers were washed with H2O (3 × 150 mL) and brine
(2 × 150 mL), dried over anh. Na2SO4 and the solvent was
evaporated in vacuo. The resulting oily residue was
chromatographed on silica gel column to afford the title
N-benzylated products 7b–9b.
2-(2,5-Dioxo-2′,3′-dihydrospiroĳimidazolidine-4,1′-inden]-1-
yl)acetic acid (10). Prepared from benzyl ester 7 (420 mg, 1.2
mmol) by catalytic hydrogenolysis in a mixture of EtOH/
AcOEt 3 : 1 (24 mL), following the previously described gen-
eral procedure for the preparation of carboxylic acids. Evapo-
ration of the solvents under reduced pressure afforded the ti-
tle compound 10 as a white crystalline solid (310 mg, almost
quantitative yield); mp 237–239 °C (from AcOEt/n-pentane),
Rf = 0.06 (AcOEt).
1H NMR (600.11 MHz, DMSO-d6) δ (ppm)
2.22 (dt, 1H, J1 = 13.3 Hz, J2 = 7.8 Hz, H2′), 2.55 (dt, 1H, J1 =
13.2 Hz, J2 = 6.5 Hz, H2′), 3.05 (t, 2H, J = 7.2 Hz, H3′), 4.07–
4.15 (q, AB, 2H, JAB = 17.5 Hz, NCH2COOH), 7.19 (d, 1H, J =
7.5 Hz, H7′), 7.26 (tdd, 1H, J1 = 7.0 Hz, J2 = 1.9 Hz, J3 = 1.0
Hz, H6′), 7.33 (td, 1H, J1 = 7.5 Hz, J2 = 1.2 Hz, H5′), 7.34–7.36
(m, 1H, H4′), 8.84 (s, 1H, H3), 13.12 (br s, 1H, NCH2COOH);
13C NMR (150.9 MHz, DMSO-d6) δ (ppm) 29.7 (C3′), 36.0 (C2′),
39.1 (NCH2COOH), 70.8 (C1′/C4), 123.1 (C7′), 125.0 (C4′), 127.0
(C6′), 129.0 (C5′), 141.0 (C7a′), 143.9 (C3a′), 155.2 (C2O), 168.7
(NCH2COOH), 175.2 (C5O). Found: C, 60.08; H, 4.70; N,
10.79. Calc. for C13H12N2O4: C, 60.00; H, 4.65; N, 10.76%.
N-(Phenylmethoxy)-2-(2,5-dioxo-2 ′,3 ′ -dihydrospiro-
ĳimidazolidine-4,1′-inden]-1-yl)acetamide (13). Carboxylic acid
10 (260 mg, 1.0 mmol) was treated with EDCI·HCl (230 mg,
1.2 mmol), HOBt (203 mg, 1.2 mmol, 80% monohydrate),
O-benzylhydroxylamine hydrochloride (192 mg, 1.2 mmol)
and TEA (587 mg, 5.8 mmol) in 10 mL dry CH2Cl2/dry DMF
(4 : 1) following the general procedure for the preparation of
O-benzyl hydroxamates (Method A). After removal of CH2Cl2
under reduced pressure, the reaction mixture was poured
into 20 mL ice-water and extracted with AcOEt (4 × 20 mL).
The combined organic layers were washed with H2O (3 × 35
mL) and brine (2 × 35 mL), dried over Na2SO4 and concen-
trated to dryness in vacuo. The oily pale-yellow residue was
purified by column chromatography on silica gel eluting first
with CH2Cl2/AcOEt 8 : 1, 5 : 1 and then AcOEt to give the corre-
sponding O-benzyl hydroxamate 13 as a white foamy solid,
which strongly binds the eluting solvents. Removal of the
entrapped solvents upon drying under high vacuum and
treatment with n-pentane at 0 °C gave 13 as a white crystal-
line solid (260 mg, 71%); mp 154–156 °C (AcOEt/n-pentane),
Rf = 0.06 (from CH2Cl2/AcOEt 8 : 1).
1H NMR (600.11 MHz,
DMSO-d6) δ (ppm) 2.22 (dt, 1H, J1 = 13.5 Hz, J2 = 7.7 Hz, H2′),
2.57 (dt, 1H, J1 = 13.1 Hz, J2 = 6.6 Hz, H2′), 3.05 (t, 2H, J = 7.1
Hz, H3′), 3.92–4.01 (q, AB, 1.55H, JAB = 16.3 Hz, NCH2CO),
4.25 (br s, 0.3H, NCH2CO), 4.81, 4.86 (s + s, 2H, OCH2Ph),
7.25–7.30 (m, 2H, H6′, H7′), 7.31–7.35 (m, 2H, H4′, H5′), 7.35–
7.47 (m, 5H, H2″, H3″, H4″, H5″, H6″), 8.81 (s, 1H, H3), 11.02 (s,
0.1H, CONHOCH2Ph), 11.39 (s, 0.7H, CONHOCH2Ph);
13C
NMR (150.9 MHz, DMSO-d6) δ (ppm) 29.7 (C3′), 36.0 (C2′),
38.0 (NCH2CO), 70.8 (C1′/C4), 77.0 (OCH2Ph), 123.3 (C7′),
124.9 (C4′), 127.0 (C6′), 128.3 (C3″, C4″, C5″), 128.8 (C2″, C6″),
129.0 (C5′), 135.8 (C1″), 141.1 (C7a′), 143.9 (C3a′), 155.3
(C2O), 163.6 (CONHOCH2Ph), 175.4 (C5O). Found: C,
65.69; H, 5.30; N, 11.53. Calc. for C20H19N3O4: C, 65.74; H,
5.24; N, 11.50%.
N-Hydroxy-2-(2,5-dioxo-2′,3′-dihydrospiroĳimidazolidine-
4,1′-inden]-1-yl)acetamide (16). A solution of the appropriate
O-benzyl hydroxamate 13 (200 mg, 0.55 mmol) in a mixture
of EtOH/AcOEt (3 : 1, 22 mL) was hydrogenated following the
general procedure described above for the preparation of
acetohydroxamic acids. Evaporation of the solvents in vacuo
yielded the title compound 16 as a white foamy solid, which
strongly binds the aforementioned solvents. Removal of the
entrapped solvents upon drying under high vacuum gave 16
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treatment with n-pentane-dry Et2O 5 : 1 under ice-cooling (150
mg, almost quantitative yield); mp 179–182 °C (from AcOEt/n-
pentane-dry Et2O), Rf = 0.29 (AcOEt). This compound
appeared in the 1H and 13C NMR spectra as a mixture of E/Z
conformers. 1H NMR (600.11 MHz, DMSO-d6) δ (ppm) 2.22
(dt, 1H, J1 = 13.4 Hz, J2 = 7.5 Hz, H2′), 2.56 (ddd, 1H, J1 = 13.4
Hz, J2 = 7.5 Hz, J3 = 6.0 Hz, H2′), 3.04 (ddd, 2H, J1 = 8.2 Hz, J2
= 6.5 Hz, J3 = 2.4 Hz, H3′), 3.91–4.00 (q, AB, 1.5H, JAB = 16.5
Hz, NCH2CO, E-isomer), 4.20–4.29 (q, AB, 0.45H, JAB = 17.5
Hz, NCH2CO, Z-isomer), 7.23–7.35 (complex m, 4H, H4′, H5′,
H6′, H7′), 8.73 (s, 0.1H, H3), 8.76, 8.77 (s + s, 0.9H, H3), 8.95
(s, 0.6H, CH2CONHOH, E-isomer), 9.33 (s, 0.2H, NCH2-
CONHOH, Z-isomer), 10.29 (s, 0.2H, NCH2CONHOH,
Z-isomer), 10.72 (s, 0.6H, CH2CONHOH, E-isomer);
13C NMR
(150.9 MHz, DMSO-d6) δ (ppm) 29.8 (C3′), 36.0, 36.1 (C2′), 38.0
(NCH2CO, E-isomer), 38.5 (NCH2CO, Z-isomer), 70.8 (C1′/C4),
123.4 (C7′), 124.9 (C4′), 127.0 (C6′), 129.0 (C5′), 141.3 (C7a′),
143.9 (C3a′), 155.4 (C2O, E-isomer), 155.6 (C2O, Z-isomer),
163.3 (NCH2CO, E-isomer), 168.7 (NCH2CO, Z-isomer), 175.5
(C5O, E-isomer), 175.7 (C5O, Z-isomer). Found: C, 56.78;
H, 4.81; N, 15.30. Calc. for C13H13N3O4: C, 56.72; H, 4.75; N,
15.27%.
2-(3-Methyl-2,5-dioxo-2′,3′-dihydrospiroĳimidazolidine-4,1′-
inden]-1-yl)acetic acid (10a). It was prepared by hydro-
genolysis of the corresponding benzyl ester 7a (320 mg, 0.88
mmol) in a mixture of 18 mL EtOH/AcOEt (3 : 1), following
the general procedure for the preparation of carboxylic acids.
After removal of the solvent under reduced pressure, the title
compound 10a was obtained as a white crystalline solid (240
mg, almost quantitative yield); mp 203–205 °C (melted gradu-
ally from 198 °C) (AcOEt/n-pentane), Rf = 0.24 (AcOEt).
1H
NMR (400.13 MHz, MeOD-d4) δ (ppm) 2.40 (ddd, 1H, J1 = 13.9
Hz, J2 = 8.4 Hz, J3 = 6.8 Hz, H2′), 2.56 (ddd, 1H, J1 = 14.0 Hz,
J2 = 8.3 Hz, J3 = 5.7 Hz, H2′), 2.69 (s, 3H, NCH3), 3.07–3.22 (m,
2H, H3′), 4.21–4.34 (q, AB, 2H, JAB = 17.6 Hz, NCH2COOH),
5.13 (br s, 1H, NCH2COOH), 7.20 (d, 1H, J = 7.3 Hz, H7′),
7.22–7.29 (m, 1H, H6′), 7.31–7.38 (m, 2H, H4′, H5′);
13C NMR
(50.32 MHz, MeOD-d4) δ (ppm) 25.4 (NCH3), 31.4 (C3′), 33.5
(C2′), 40.4 (NCH2COOH), 76.5 (C1′/C4), 124.5 (C7′), 126.4 (C4′),
128.4 (C6′), 130.9 (C5′), 139.0 (C7a′), 146.4 (C3a′), 156.6 (C2O),
170.3 (NCH2COOH), 176.6 (C5O). Found: C, 61.29; H, 5.21;
N, 10.28. Calc. for C14H14N2O4: C, 61.31; H, 5.15; N, 10.21%.
N-(Phenylmethoxy)-2-(3-methyl-2,5-dioxo-2′,3′-dihydrospiro-
ĳimidazolidine-4,1′-inden]-1-yl)acetamide (13a). Using the
general procedure for the preparation of
N-(phelylmethoxy)acetamides (Method B), the carboxylic acid
precursor 10a (200 mg, 0.73 mmol) was treated with CDI (143
mg, 0.88 mmol), O-benzylhydroxylamine hydrochloride (140
mg, 0.88 mmol) and TEA (135 mg, 1.33 mmol) in dry THF (9
mL). After removal of the solvent in vacuo, the reaction mix-
ture was quenched with 15 mL ice-water and extracted with
AcOEt (4 × 15 mL). The combined organic phases were
washed with H2O (3 × 25 mL) and brine (2 × 25 mL), dried
over anh. Na2SO4 and evaporated under reduced pressure.
The pale-yellow viscous oily residue was purified by column
chromatography on silica gel using CH2Cl2, CH2Cl2/AcOEt
20 : 1, 10 : 1 and AcOEt as eluents to afford the corresponding
O-benzyl hydroxamate 13a as a colorless oil, which was fur-
ther crystallized to a white crystalline solid by treatment with
n-pentane under ice-cooling (210 mg, 76%); mp 108–110 °C
(from AcOEt/n-pentane-dry Et2O), Rf = 0.21 (CH2Cl2/AcOEt 8 :
1). 1H NMR (600.11 MHz, DMSO-d6) δ (ppm) 2.41 (ddd, 1H, J1
= 14.4 Hz, J2 = 8.5 Hz, J3 = 6.7 Hz, H2′), 2.48 (ddd, 1H, J1 =
14.3 Hz, J2 = 8.3 Hz, J3 = 6.0 Hz, H2′), 2.62 (s, 3H, NCH3),
3.05–3.16 (m, 2H, H3′), 3.96–4.06 (q, AB, 1.6H, JAB = 16.2 Hz,
NCH2CO), 4.27 (br s, 0.3H, NCH2CO), 4.81, 4.86 (s + s, 2H,
OCH2Ph), 7.22 (d, 1H, J = 7.6 Hz, H7′), 7.29 (t, 1H, J = 7.2 Hz,
H6′), 7.33–7.47 (m, 7H, H4′, H5′, H2″, H3″, H4″, H5″, H6″), 11.06
(s, 0.1H, CONHOCH2Ph), 11.40 (s, 0.7H, CONHOCH2Ph);
13C
NMR (150.9 MHz, DMSO-d6) δ (ppm) 24.7 (NCH3), 30.0 (C3′),
32.1 (C2′), 38.4 (NCH2CO), 74.3 (C1′/C4), 77.0 (OCH2Ph), 123.4
(C7′), 125.2 (C4′), 127.2 (C6′), 128.3 (C3″, C4″, C5″), 128.8 (C2″,
C6″), 129.5 (C5′), 135.7 (C1″), 138.0 (C7a′), 144.7 (C3a′), 155.3
(C2O), 163.6 (CONHOCH2Ph), 175.4 (C5O). Found: C,
66.54; H, 5.61; N, 11.00. Calc. for C21H21N3O4: C, 66.48; H,
5.58; N, 11.08%.
N-Hydroxy-2-(3-methyl-2,5-dioxo-2 ′,3 ′-dihydrospiro-
ĳimidazolidine-4,1′-inden]-1-yl)acetamide (16a). A mixture of
the O-benzyl hydroxamate 13a (160 mg, 0.42 mmol) and Pd
on charcoal (19 mg) in EtOH/AcOEt 3 : 1 (17 mL) was
subjected to catalytic hydrogenolysis in exactly the same pro-
cedure described above for the preparation of the final com-
pounds. Removal of the solvents under reduced pressure pro-
vided the acetohydroxamic acid 16a as a white foamy solid.
Crystallization of this product upon treatment with
n-pentane-dry Et2O under ice-cooling gave a white crystalline
solid (120 mg, almost quantitative yield); mp melted gradu-
ally from 158 °C to 162 °C (AcOEt/n-pentane-dry Et2O), Rf =
0.22 (from AcOEt). This compound exhibited distinct peaks
attributed to each of the two E/Z conformers in the 1H and
13C NMR spectra. 1H NMR (600.11 MHz, DMSO-d6) δ (ppm)
2.40 (ddd, 1H, J1 = 14.1 Hz, J2 = 8.5 Hz, J3 = 4.2 Hz, H2′), 2.47
(ddd, 1H, J1 = 14.1 Hz, J2 = 8.2 Hz, J3 = 4.0 Hz, H2′), 2.61 (s,
3H, NCH3), 3.04–3.16 (m, 2H, H3′), 3.95–4.04 (q, AB, 1.5H, JAB
= 16.1 Hz, NCH2CO, E-isomer), 4.24–4.33 (q, AB, 0.5H, JAB =
17.3 Hz, NCH2CO, Z-isomer), 7.23 (d, 1H, J = 7.8 Hz, H7′),
7.27 (td, 1H, J1 = 7.3 Hz, J2 = 2.0 Hz, H6′), 7.34–7.40 (m, 2H,
H4′, H5′), 8.98 (s, 0.7H, CH2CONHOH, E-isomer), 9.36 (s,
0.23H, NCH2CONHOH, Z-isomer), 10.34 (s, 0.23H, NCH2-
CONHOH, Z-isomer), 10.75 (s, 0.7H, CH2CONHOH,
E-isomer); 13C NMR (150.9 MHz, DMSO-d6) δ (ppm) 24.8
(NCH3), 30.1 (C3′), 32.1 (C2′), 38.5 (NCH2CO, E-isomer), 39.0
(NCH2CO, Z-isomer), 74.3 (C1′/C4), 123.5, 123.6 (C7′), 125.2
(C4′), 127.2 (C6′), 129.5 (C5′), 138.2 (C7a′), 144.7 (C3a′), 154.6
(C2O, E-isomer), 154.7 (C2O, Z-isomer), 163.2 (NCH2CO,
E-isomer), 168.6 (NCH2CO, Z-isomer), 174.6 (C5O,
E-isomer), 174.8 (C5O, Z-isomer). Found: C, 58.23; H, 5.26;
N, 14.50. Calc. for C14H15N3O4: C, 58.13; H, 5.23; N, 14.53%.
Benzyl 2-(3-benzyl-2,5-dioxo-2′,3′-dihydrospiro-
ĳimidazolidine-4,1′-inden]-1-yl)acetate (7b). A stirred solution
of benzyl ester 7 (600 mg, 1.71 mmol) in dry DMF (7.6 mL)
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mineral oil) and benzyl bromide (351 mg, 2.05 mmol) by
employing the N-alkylation reaction described above. The re-
action mixture was poured into an ice-water mixture (80 mL)
and extracted with AcOEt (3 × 60 mL). The combined organic
phases were washed with H2O (3 × 100 mL) and brine (2 ×
100 mL), dried over anh. Na2SO4 and evaporated under re-
duced pressure. The brownish-yellow crude oily residue was
purified by silica gel column chromatography. CH2Cl2 was
used as eluent to afford the target compound 7b as a white
crystalline solid (510 mg, 68%); mp 129–131 °C (from AcOEt/
n-pentane), Rf = 0.76 (CH2Cl2/AcOEt 8 : 1).
1H NMR (600.11
MHz, CDCl3) δ (ppm) 2.05 (ddd, 1H, J1 = 14.2 Hz, J2 = 8.9 Hz,
J3 = 5.5 Hz, H2′), 2.52 (ddd, 1H, J1 = 13.8 Hz, J2 = 9.1 Hz, J3 =
5.6 Hz, H2′), 2.84 (ddd, 1H, J1 = 16.0 Hz, J2 = 8.9 Hz, J3 = 5.6
Hz, H3′), 3.07 (ddd, 1H, J1 = 15.9 Hz, J2 = 9.1 Hz, J3 = 5.5 Hz,
H3′), 3.81 (d, 1H, J = 15.9 Hz, NCHHPh), 4.41–4.49 (q, AB, 2H,
JAB = 17.3 Hz, NCH2COO), 4.82 (d, 1H, J = 15.9 Hz, NCHHPh),
5.20–5.26 (q, AB, 2H, JAB = 12.1 Hz, OCH2Ph), 7.06 (d, 1H, J =
7.7 Hz, H7′), 7.10–7.13 (m, 2H, H2Bz, H6Bz), 7.14 (td, 1H, J1 =
7.4 Hz, J2 = 1.3 Hz, H6′), 7.21–7.27 (complex m, 3H, H3Bz,
H4Bz, H5Bz), 7.28 (dt, 1H, J1 = 7.5 Hz, J2 = 1.1 Hz, H4′), 7.31
(td, 1H, J1 = 7.4 Hz, J2 = 1.1 Hz, H5′), 7.34–7.41 (m, 5H, H2″,
H3″, H4″, H5″, H6″);
13C NMR (150.9 MHz, CDCl3) δ (ppm) 30.7
(C3′), 33.9 (C2′), 40.1 (NCH2COO), 44.1 (NCH2Ph), 67.9
(COOCH2Ph), 76.0 (C1′/C4), 124.0 (C7′), 125.4 (C4′), 127.7 (C2Bz,
C6Bz), 127.8 (C6′), 128.6 (C3Bz, C5Bz), 128.7 (C2″, C6″, C4Bz),
128.76 (C4″), 128.84 (C3″, C5″), 130.0 (C5′), 135.0 (C1″), 137.5
(C1Bz), 137.9 (C7a′), 145.1 (C3a′), 155.7 (C2O), 167.3
(COOCH2Ph), 175.0 (C5O). Found: C, 73.66; H, 5.55; N,
6.30. Calc. for C27H24N2O4: C, 73.62; H, 5.49; N, 6.36%.
2-(3-Benzyl-2,5-dioxo-2′,3′-dihydrospiroĳimidazolidine-4,1′-
inden]-1-yl)acetic acid (10b). Prepared from benzyl ester 7b
(400 mg, 0.91 mmol) by catalytic hydrogenolysis in a mix-
ture of 18 mL EtOH/AcOEt (3 : 1) following the procedure de-
scribed for the preparation of the above-mentioned carbox-
ylic acids. The desired compound 10b was afforded as a
glass solid, which was further crystallized upon treatment
with n-pentane-dry Et2O (5 : 1) under ice-cooling to give a
white crystalline solid (316 mg, almost quantitative yield);
mp 144–147 °C (from AcOEt/n-pentane), Rf = 0.22 (AcOEt).
1H NMR (600.11 MHz, DMSO-d6) δ (ppm) 2.14 (ddd, 1H, J1
= 14.1 Hz, J2 = 8.7 Hz, J3 = 5.6 Hz, H2′), 2.44 (ddd, 1H, J1 =
14.5 Hz, J2 = 8.9 Hz, J3 = 5.9 Hz, H2′), 2.93 (ddd, 1H, J1 =
15.8 Hz, J2 = 8.7 Hz, J3 = 5.9 Hz, H3′), 3.00 (ddd, 1H, J1 =
15.0 Hz, J2 = 8.9 Hz, J3 = 5.6 Hz, H3′), 3.96 (d, 1H, J = 16.3
Hz, NCHHPh), 4.19–4.27 (q, AB, 2H, JAB = 17.4 Hz, NCH2-
COOH), 4.58 (d, 1H, J = 16.3 Hz, NCHHPh), 7.07–7.14 (m,
3H, H7′, H2Bz, H6Bz), 7.15–7.26 (complex m, 4H, H6′, H3Bz,
H4Bz, H5Bz), 7.30–7.35 (m, 2H, H4′, H5′), 13.33 (br s, 1H,
NCH2COOH);
13C NMR (150.9 MHz, DMSO-d6) δ (ppm) 30.0
(C3′), 33.0 (C2′), 40.1 (NCH2COOH), 43.2 (NCH2Ph), 74.9 (C1′/
C4), 123.6 (C7′), 125.2 (C4′), 127.1 (C6′, C2Bz, C4Bz, C6Bz), 128.2
(C3Bz, C5Bz), 129.5 (C5′), 137.6 (C1Bz), 138.3 (C7a′), 144.7
(C3a′), 155.1 (C2O), 168.7 (NCH2COOH), 174.3 (C5O).
Found: C, 68.60; H, 5.14; N, 8.13. Calc. for C20H18N2O4: C,
68.56; H, 5.18; N, 8.00%.
N-(Phenylmethoxy)-2-(3-benzyl-2,5-dioxo-2′,3′-dihydrospiro-
ĳimidazolidine-4,1′-inden]-1-yl)acetamide (13b). Prepared
from carboxylic acid 10b (290 mg, 0.83 mmol) upon treat-
ment with CDI (162 mg, 1.0 mmol), O-benzylhydroxylamine
hydrochloride (160 mg, 1.00 mmol) and TEA (153 mg, 1.51
mmol) in dry THF (11 mL), following the general procedure
for the synthesis of O-benzyl hydroxamates (Method B). After
removal of THF under reduced pressure, the reaction mixture
was quenched with 20 mL ice-water and extracted with AcOEt
(4 × 20 mL). The combined organic layers were washed with
H2O (3 × 35 mL) and brine (2 × 35 mL), dried with anh.
Na2SO4 and evaporated in vacuo. The resulting viscous oily
residue was chromatographed on silica gel using CH2Cl2,
CH2Cl2/AcOEt 20 : 1, 10 : 1 and AcOEt as eluents to give the
corresponding O-benzyl hydroxamate 13b as a glass solid.
Crystallization of this material upon treatment with a
n-pentane-dry Et2O mixture (5 : 1) gave a white crystalline
solid (310 mg, 82%); mp melted gradually from 60 °C to 78
°C (from AcOEt/n-pentane-dry Et2O), Rf = 0.41 (CH2Cl2/AcOEt
8 : 1). 1H NMR (600.11 MHz, DMSO-d6) δ (ppm) 2.13 (ddd,
1H, J1 = 14.0 Hz, J2 = 8.6 Hz, J3 = 5.3 Hz, H2′), 2.45 (ddd, 1H,
J1 = 14.5 Hz, J2 = 8.9 Hz, J3 = 6.0 Hz, H2′), 2.93 (ddd, 1H, J1 =
15.8 Hz, J2 = 8.6 Hz, J3 = 6.0 Hz, H3′), 2.99 (ddd, 1H, J1 = 14.9
Hz, J2 = 8.8 Hz, J3 = 5.4 Hz, H3′), 3.94 (d, 1H, J = 16.3 Hz,
NCHHPh), 4.04–4.13 (q, AB, 1.65H, JAB = 16.2 Hz, NCH2CO),
4.35 (br s, 0.35H, NCH2CO), 4.58 (d, 1H, J = 16.2 Hz,
NCHHPh), 4.82, 4.89 (s + s, 2H, OCH2Ph), 7.13 (d, 1H, J = 7.2
Hz, H2Bz, H6Bz), 7.16–7.26 (m, 5H, H6′, H7′, H3Bz, H4Bz, H5Bz),
7.30–7.35 (m, 2H, H4′, H5′), 7.35–7.49 (m, 5H, H2″, H3″, H4″,
H5″, H6″), 11.09 (s, 0.15H, CONHOCH2Ph), 11.46 (s, 0.75H,
CONHOCH2Ph);
13C NMR (150.9 MHz, DMSO-d6) δ (ppm)
30.0 (C3′), 33.0 (C2′), 38.6 (NCH2CO), 43.1 (NCH2Ph), 74.9 (C1′/
C4), 77.0 (OCH2Ph), 123.8 (C7′), 125.1 (C4′), 127.1 (C6′, C2Bz,
C4Bz, C6Bz), 128.2 (C3Bz, C5Bz), 128.3 (C2″, C4″, C6″), 128.8 (C3″,
C5″), 129.5 (C5′), 135.7 (C1″), 137.6 (C1Bz), 138.4 (C7a′), 144.7
(C3a′), 155.2 (C2O), 163.5 (CONHOCH2Ph), 174.5 (C5O).
Found: C, 71.25; H, 5.60; N, 9.32. Calc. for C27H25N3O4: C,
71.19; H, 5.53; N, 9.22%.
N-Hydroxy-2-(3-benzyl-2,5-dioxo-2 ′,3 ′-dihydrospiro-
ĳimidazolidine-4,1′-inden]-1-yl)acetamide (16b). The
N-benzyloxy precursor 13b (250 mg, 0.55 mmol) was
subjected to catalytic hydrogenation in a mixture of EtOH/
AcOEt 3 : 1 (22 mL) according to the previously described
procedure for the synthesis of hydroxamate analogues. Con-
centration to dryness of the solvents under reduced pressure
yielded the title compound 16b as a white crystalline solid
(200 mg, almost quantitative yield); mp melted gradually
from 174 °C to 181 °C (from AcOEt/n-pentane-dry Et2O), Rf =
0.49 (AcOEt). In the 1H and 13C NMR spectra of this com-
pound, double set of characteristic peaks are distinguished
for each of the two E/Z conformers. 1H NMR (600.11 MHz,
DMSO-d6) δ (ppm) 2.13 (ddd, 1H, J1 = 13.9 Hz, J2 = 8.6 Hz,
J3 = 5.4 Hz, H2′), 2.44 (ddd, 1H, J1 = 13.9 Hz, J2 = 8.9 Hz, J3
= 6.1 Hz, H2′), 2.92 (ddd, 1H, J1 = 16.0 Hz, J2 = 8.5 Hz, J3 =
6.3 Hz, H3′), 2.98 (ddd, 1H, J1 = 14.4 Hz, J2 = 8.9 Hz, J3 =
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(q, AB, 1.5H, JAB = 16.0 Hz, NCH2CO, E-isomer), 4.32–4.40
(q, AB, 0.5H, JAB = 17.4 Hz, NCH2CO, Z-isomer), 4.57 (dd,
1H, J1 = 16.3 Hz, J2 = 8.8 Hz, NCHHPh), 7.12 (d, 1H, J = 6.7
Hz, H2Bz, H6Bz), 7.15–7.25 (complex m, 5H, H6′, H7′, H3Bz,
H4Bz, H5Bz), 7.29–7.34 (m, 2H, H4′, H5′), 9.03 (s, 0.68H, CH2-
CONHOH, E-isomer), 9.41 (s, 0.22H, NCH2CONHOH,
Z-isomer), 10.37 (s, 0.22H, NCH2CONHOH, Z-isomer), 10.80
(s, 0.68H, CH2CONHOH, E-isomer);
13C NMR (150.9 MHz,
DMSO-d6) δ (ppm) 30.0 (C3′), 32.9, 33.0 (C2′), 38.6 (NCH2CO,
E-isomer), 39.1 (NCH2CO, Z-isomer), 43.1 (NCH2Ph), 74.9
(C1′/C4), 123.9 (C7′), 125.0 (C4′), 127.1 (C6′, C2Bz, C4Bz, C6Bz),
128.2 (C3Bz, C5Bz), 129.5 (C5′), 137.6 (C1Bz), 138.5 (C7a′), 144.7
(C3a′), 155.3 (C2O, E-isomer), 155.5 (C2O, Z-isomer),
163.2 (NCH2CO, E-isomer), 168.6 (NCH2CO, Z-isomer), 174.6
(C5O, E-isomer), 174.8 (C5O, Z-isomer). Found: C, 65.79;
H, 5.18; N, 11.55. Calc. for C20H19N3O4: C, 65.74; H, 5.24; N,
11.50%.
Biology
Cell culture. Huh5-2 (ref. 61) cells (kindly provided by R.
Bartenschlager, University of Heidelberg, Germany) contain
the subgenomic HCV reporter replicon I389luc-ubi-neo/NS3-3′/
Con1/5.1 (genotype 1b; strain Con1). This replicon is com-
posed of the HCV 5′ UTR possessing an internal ribosome en-
try site (IRES) that directs the expression of a firefly lucifer-
ase–ubiquitin–neomycin phosphotransferase fusion protein
(luc-ubi-neo). Downstream of this reporter protein is the IRES
of the encephalomyocarditis virus (EMCV) that mediates
translation of the HCV NS3 to NS5B coding region, followed
by the HCV 3′ UTR. The expression of the luc-ubi-neo fusion
protein enables the selection for cells containing the replicon
using neomycin/G418 and the assessment of viral RNA repli-
cation by measuring the activity of the reporter protein firefly
luciferase (F-Luc). Stable cell lines Huh7.5-3a and Huh7.5-4a
harbor the HCV bicistronic replicons S52-SG (Feo) (AII) and
ED43-SG (Feo)(VYG) (kindly provided by C. M. Rice, The
Rockefeller University, NY)67 of the analogous design and
were previously described.68 HCV sequences were derived
from the genotype 3a strain S52 and the genotype 4a strain
ED43. DENV bicistronic replicon plasmid pD2-hRUPac
(kindly provided by C. M. Rice) has been described previ-
ously.69 The structural protein-coding region between capsid
gene codon 28 and the last 26 codons at the 3′ end of the en-
velope gene from an infectious clone of dengue 2 virus
(DEN2) 16681 have been replaced by a humanized Renilla lu-
ciferase–ubiquitin–puromycin acetyltransferase (hRUPac) cas-
sette. A stable cell line (Huh7-D2) was generated by trans-
fecting Huh7 cells with the above replicon RNA and pooling
colonies after selection with 0.5 μg ml−1 puromycin. Cells
were cultured in high glucose (25 mM) Dulbecco's modified
minimal essential medium (Invitrogen), supplemented with 2
mM L-glutamine, 0.1 mM non-essential amino acids, 100 U
mL−1 penicillin, 100 μg mL−1 streptomycin and 10% (v/v) fetal
calf serum (referred to as complete DMEM). Complete DMEM
was supplemented with 500 μg mL−1 G418 for Huh5-2, 750
μg ml−1 G418 for Huh7.5-3a, 350 μg mL−1 G418 for Huh7.5-4a
and 0.5 μg ml−1 puromycin for Huh7-D2.
In vitro transcription. Bicistronic DENV constructs were
linearized with XbaI and used for in vitro transcription as de-
scribed previously.70
Transfection with in vitro transcribed RNA. Electropora-
tion with bicistronic DENV RNA into Huh7 cells was
performed as described elsewhere.71
Cell-based antiviral assays. Replicon assays were performed
by seeding 1 × 104 cells per well in a 96-well flat bottom plate,
cultured in 200 μL complete DMEM supplemented with selec-
tion antibiotic. After 24 h incubation at 37 °C (5% CO2), me-
dium was removed and serial dilutions (without G418) of the
test compounds in complete DMEM were added, in a total vol-
ume of 100 μL. After 3 days of incubation at 37 °C, cells were
lysed and F-Luc or R-Luc activity was measured. Relative lumi-
nescence units (RLU) were calculated as percentage of the re-
spective values from DMSO-treated control cells. The half maxi-
mal effective concentration (EC50) was defined as the
concentration of compound that reduced the luciferase signal
by 50%. EC50 values were determined by nonlinear regression
analysis after converting the drug concentrations into logX
using the Prism 5.0 software (GraphPad Software Inc.).
Luciferase and Bradford assays. Firefly luciferase (F-Luc)
activity in cell lysate was measured using Luciferase Assay
System (Promega), as recommended by the manufacturer.
Renilla luciferase (R-Luc) activity in cell lysates was measured
using 12 μM coelenterazine (Promega) in assay buffer (50
mM potassium phosphate, pH 7.4, 500 mM NaCl, 1 mM
EDTA). Measurements were taken in a GloMax 20/20 single-
tube luminometer (Promega) for 10 s. Luciferase activities
were normalized to the total protein amount determined
using the Bradford assay reagent (Bio-Rad).
Cytotoxicity assay. Cytotoxicity of the compounds was de-
termined by measuring intracellular ATP levels. Specifically,
104 cells per well were seeded in 96-well flat bottom plates in
total volume of 100 μL complete DMEM. After 24 h, cells were
incubated with the compounds for 72 h at 37 °C (5% CO2)
and lysed for ATP measurement. Calculation of the com-
pound concentration causing 50% cell death (CC50) was
performed using cells treated with DMSO as control sample.
CC50 values were determined by nonlinear regression analysis
after converting the drug concentrations into logX using the
Prism 5.0 software (GraphPad Software Inc.).
Measurement of intracellular ATP levels. ATP was mea-
sured using the ViaLight HS BioAssay kit (Lonza) according
to the manufacturer's protocol in a GloMax 20/20 single-tube
luminometer (Promega) for 1 s. ATP levels were normalized
to total protein amounts.
Indirect immunofluorescence. Indirect immunofluores-
cence analysis of HCV-4a NS5A was performed as described
elsewhere.71 DNA was stained with propidium iodide (Sigma-
Aldrich). Images were acquired with the Leica TCS-SP8 Confo-
cal Microscope.
Total RNA extraction and quantification of viral replicons.
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reagent (Ambion), according to the manufacturer's instruc-
tions. Replicon RNA was quantified with reverse-transcription
(RT) and quantitative real-time polymerase chain reaction
(qPCR). For RT, the IRES specific primer 5′-GGATTCGTGCT
CATGGTGCA-3′ (reverse) and Moloney murine leukemia virus
(MMLV) reverse transcriptase (Promega) were used. For
qPCR, the IRES specific primers 5′-GGCCTTGTGGTACTGC
CTGATA-3′ (forward) and 5′-GGATTCGTGCTCATGGTGCA-3′
(reverse) and KAPA SYBR FAST qPCR Master Mix (Kapa Bio-
systems) were used. The housekeeping gene YWHAZ was
employed as an internal control (primers 5′-GCTGGTGATGA
CAAGAAAGG-3′ and 5′-GGATGTGTTGGTTGCATTTCCT-3′).
Statistical analysis. In all diagrams, bars represent mean
values of at least two independent experiments in triplicate.
Error bars represent standard deviation. Only results
subjected to statistical analysis using Student's t-test with p
≤ 0.05 were considered as statistically significant and
presented. Statistical calculations were carried out using Ex-
cel Microsoft Office®.
Trypanocidal assays. Bloodstream form T. brucei (strain
221) were cultured in modified Iscove's medium, as outlined
previously.72 Eight-point potency curves were performed in 96-
well plates (200 μL volumes), and the compound concentra-
tions that inhibited growth by 50% (EC50) and 90% (EC90) were
determined. Parasites were first diluted to 2.5 × 104 mL−1, com-
pounds were added at range of concentrations, and the plates
incubated at 37 °C. Resazurin was added after 48 h, and the
plates incubated for a further 16 h. T. cruzi epimastigotes
(strain CL Brener) were cultured as previously described.73
Trypanocidal activity was determined in microtiter plates as
outlined above, with the following modifications. Experiments
were initiated by seeding the parasites at 2.5 × 105 ml−1, and af-
ter the addition of test compounds, cultured at 28 °C for 4
days. Resazurin was added, the plates were incubated for a fur-
ther 2 days, and then assessed as above. Fluorescence intensi-
ties were determined using a BMG FLUOstar Omega (excitation
545 nm, emission 590 nm). Data were analyzed using Graph
Pad Prism 7 software. Values are expressed as EC50 ± SD and
are the average of three independent replicates.
In vitro cytotoxicity assays on rat skeletal myoblast L6
cells. Cytotoxicity against L6 cells was assessed using microti-
ter plates. Briefly, cells were seeded in triplicate at 1 × 104
mL−1 in growth medium containing different compound con-
centrations. The plates were incubated for 6 days at 37 °C
and resazurin then added to each well. After a further 8 h in-
cubation, the fluorescence was determined using a BMG
FLUOstar Omega plate reader.
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